Third Century Bancorp Announces Dividend

Third Century Bancorp (OTC: TDCB) announced a cash dividend of $0.05 per share, declared on February 26, 2026, for shareholders of record on March 18, 2026, payable on April 2, 2026.

(Low)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

dividends

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/27/2026 - 12:07 PM

FRANKLIN, Ind.--(BUSINESS WIRE)-- (OTCID: TDCB) — Third Century Bancorp, an Indiana corporation and parent company of Mutual Savings Bank, announced that on February 26, 2026, the Board of Directors declared a dividend of $0.05 per share for shareholders of record on March 18, 2026. The dividend payable date is April 2, 2026.

Founded in 1890, Mutual Savings Bank is a full-service financial institution with $349 million in assets as of December 31, 2025. In addition to its main office at 80 East Jefferson Street, Franklin, Indiana, the bank operates branches in Franklin at 1124 North Main Street, as well as in Trafalgar and Greenwood, Indiana.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260227321883/en/

David A. Coffey, President and Chief Executive Officer
S. Paul Arab, Senior Vice President and Chief Financial Officer
Tel. 317-736-7151
Fax 317-736-1726

Source: Third Century Bancorp

Keep reading

More on TDCB

Aug 20, 2026 Third Century Bancorp Announces Dividend
Jul 17, 2026 Third Century Bancorp Releases Earnings for the Quarter Ended June 30, 2026
May 20, 2026 Third Century Bancorp Announces Dividend

All TDCB news

Trending in the feed

MIRM

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Open the live feed